Phase II study of Gleevec [imatinib] and Taxotere [docetaxel] in recurrent non-small cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2016
At a glance
- Drugs Docetaxel (Primary) ; Imatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 10 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 May 2010 Planned end date changed from 1 Oct 2010 to 1 Aug 2011 as reported by ClinicalTrials.gov.